Buffl

Section IX. Neuromuscular and Spine Disorders

AW
by Angi W.

IX.12. A 38-year-old woman is referred for evaluation of progressively

worsening, fatigable weakness. The neurologic examination is

notable for mild flaccid dysarthria and moderately severe prox-

imal upper limb weakness without ocular signs or symptoms.

After she is given a provisional diagnosis of myasthenia gravis

(MG), initial therapy is begun with pyridostigmine while labora-

tory and electrodiagnostic testing is in progress. Five days after

the initiation of pyridostigmine, the patient reports worsening

symptoms, fasciculations, and excessive salivation, which seem

to be associated with the timing of pyridostigmine. Which of

the following antibodies would most likely be detected with

this patient’s laboratory evaluation?

a. Acetylcholine receptor (AChR)-binding antibodies

b. Muscle-specific kinase (MuSK) antibodies

c. Striated muscle antibodies

d. Low-density lipoprotein-related protein 4 (LRP4) antibodies

e. P/Q-type calcium channel antibodies

XI.12. Answer b.

MuSK antibodies are detected in 40% to 50% of patients

with MG who do not have AChR antibodies. Patients with

MuSK antibodies typically have generalized MG but may

have clinical features that distinguish them from patients

with AChR antibodies. MuSK MG often more prominently

affects neck, shoulder girdle, bulbar, and respiratory mus-

cles and spares ocular muscles. Many patients with MuSK

MG either will not respond to pyridostigmine or will have

adverse effects to pyridostigmine as this patient did. The

adverse response to pyridostigmine and the absence of ocu-

lar symptoms and signs are more typical of MuSK MG than

MG associated with LRP4 or AChR antibodies. Striated

muscle (or striational) antibodies may be present in younger

patients with thymoma but would not necessarily be abnor-

mal in this patient. P/Q-type calcium channel antibodies

are associated with Lambert-Eaton myasthenic syndrome.

IX.13. A 58-year-old man with a 2-month history of worsening symp-

toms attributed to myasthenia gravis (MG), including diplopia,

ptosis, and proximal limb weakness, presents to the emergency

department for new-onset swallowing and breathing issues. He

had begun taking pyridostigmine 1 month previously and had

initial benefit. On neurologic examination, he has fatigable

ptosis, proximal limb weakness (more pronounced than distal

limb weakness), and flaccid dysarthria. Which of the following

is the most appropriate next step in the management of this

patient’s condition?

a. Increase the dosage of pyridostigmine

b. Initiate a high dose of prednisone

c. Admit him to the hospital for respiratory monitoring, inspira-

tory and expiratory pressures, and initiation of immunotherapy

with either intravenous immunoglobulin or plasma exchange

d. Thymectomy

e. Initiate 3,4-diaminopyridine

IX.13. Answer c.

This patient presented in myasthenic crisis with symptoms

of bulbar impairment and dyspnea. He should be admitted

to an intensive care unit and undergo serial monitoring of

vital capacity along with inspiratory and expiratory pres-

sures. Prompt initiation of immunotherapy with either

intravenous immunoglobulin or plasma exchange is the

treatment of choice for patients with myasthenic crisis.

Typically, pyridostigmine would be discontinued so as to

not increase secretions; this potential adverse effect can be

problematic in patients with marked bulbar impairment or

myasthenic crisis. Furthermore, patients taking high doses

of pyridostigmine may be at risk for cholinergic crisis,

which can be difficult to differentiate from myasthenic cri-

sis. Initiation of a high dose of prednisone is not appropri-

ate as an initial therapeutic option in myasthenic crisis

because in a large percentage of patients the myasthenic

symptoms may worsen transiently 5 to 10 days after the

initiation of prednisone. Thymectomy, although not an

appropriate intervention in a patient with myasthenic cri-

sis, should be considered in early-onset MG for patients

who are clinically stable or who have thymoma. The drug

3,4-diaminopyridine is used to treat Lambert-Eaton myas-

thenic syndrome and would not be appropriate for this

patient.

Author

Angi W.

Information

Last changed